CORRECTION OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PREECLAMPSY BY COMBINED USE OF TRIMETAZIDINE AND PURIFIED MICRONIZED FLAVONOID FRACTION AS WELL AS THEIR COMBINATIONS WITH METHYLAMPSY

CORRECTION OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PREECLAMPSY BY COMBINED USE OF TRIMETAZIDINE AND PURIFIED MICRONIZED FLAVONOID FRACTION AS WELL AS THEIR COMBINATIONS WITH METHYLAMPSY

The aim of the experiment was to determine the effectiveness of the combined use of trimetazidine and a purified micronized flavonoid fraction, as well as their combinations with methyldopa, in comparison with monotherapy with the same drugs in the correction of morphofunctional disorders arising in...

Full description

Bibliographic Details
Main Authors:	O. E. Antsiferova, M. P. Teleshchenko, Yu. M. Tsuverkalova, M. V. Pokrovsky, V. V. Gureev, M. A. Zatolokina, A. V. Gureeva
Format:	Article
Language:	Russian
Published:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2021-03-01
Series:	Фармация и фармакология (Пятигорск)
Subjects:	триметазидин очищенная микронизированная флавоноидная фракция преэклампсия дисфункция эндотелия крысы
Online Access:	https://www.pharmpharm.ru/jour/article/view/737

Similar Items

COVID-19-associated phlebopathy as a current problem of modern phlebology
by: V. Yu. Bogachev, et al.
Published: (2022-11-01)

Chronic vein insufficiency correction in patients with lower extremities varicosity and knee osteoarthritis
by: E. A. Shcheglov, et al.
Published: (2022-11-01)

RETRACTED: Pathogenetic substantiation of phlebotropic therapy for chronic venous diseases
by: V. Yu. Bogachev, et al.
Published: (2019-11-01)

A perioperative phlebotropic therapy compliance study in patients with varicose veins
by: S. N. Zhabin, et al.
Published: (2020-06-01)

Current indications for phlebotropic therapy and its duration
by: V. Yu. Bogachev, et al.
Published: (2021-06-01)

Management of chronic venous insufficiency of the lower extremities
by: M. N. Kudykin
Published: (2018-12-01)

Comparison of the effectiveness of various conservative treatment options for trophic ulcers and varicose eczema
by: E. V. Ivanov, et al.
Published: (2021-11-01)

Diagnosis and treatment of chronic venous disease
by: V. Y. Bogachev, et al.
Published: (2016-06-01)

CORRECTION OF EXPERIMENTAL L-NAME-INDUCED PRE-ECLAMPSY BY INHIBITOR OF ARGINASE L-NORVALINE AND ITS COMBINATIONS WITH PREPARATIONS OF STANDARD TREATMENT SCHEME
by: O. S. Poljanskaja, et al.
Published: (2014-02-01)

Anti-anginal and anti-ischemic effectiveness of trimetazidine MB in patients with unstable angina
by: M. G. Glezer, et al.
Published: (2009-02-01)

Clinical effectiveness of long-term trimetazidine MB therapy in patients with cardio-respiratory disease (the results of an open, prospective multi-centre study)
by: N. M. Kolomoets, et al.
Published: (2009-12-01)

Trimetazidine effects on mitochondria energetic activity
by: S. V. Eliseeva, et al.
Published: (2008-12-01)

STUDY OF EFFECT PREKONDITSIONIRUYUSCHEGO RESVERATROL AND NICORANDIL IN THE CORRECTION OF ADMA-LIKE PRE-ECLAMPSIA
by: V. V. Gureev, et al.
Published: (2016-10-01)

The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use
by: O. V. Tsygankova, et al.
Published: (2019-12-01)

The effectiveness of cytocardioprotection of patients with the moderately expressed post infarct dysfunction of left heart ventricle: the results of the randomization research of trimetazidine and athenolole
by: V. V. Kalyuzhin, et al.
Published: (2002-03-01)

Carbohydrate metabolism parameters in angina patients treated with metoprolol and its combination with trimetazidine
by: E. V. Bochkareva, et al.
Published: (2012-08-01)

TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
by: M. V. Novikova, et al.
Published: (2014-10-01)

Trimetazidine MR effects on heart remodeling in stable coronary heart disease patients
by: E. M. Khurs, et al.
Published: (2007-02-01)

Trimetazidine in chronic heart failure patients aged above 75 years
by: I. V. Ignatenko, et al.
Published: (1970-01-01)

Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome
by: M. G. Glezer, et al.
Published: (2009-08-01)

Trimetazidine MB treatment in patients with chronic heart failure
by: T. E. Morozova, et al.
Published: (2010-06-01)

Comparing effectiveness of adding prolonged trimetazidine or isosorbide dinitrate to beta-adrenoblocker therapy in stable angina patients
by: M. G. Glezer, et al.
Published: (2006-08-01)

TRIMETAZIDINE MR EFFECTS ON THE PARAMETERS OF 24-HOUR ELECTROCARDIOGRAM MONITORING AND HEART RATE VARIABILITY
by: M. V. Novikova, et al.
Published: (2013-10-01)

Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
by: L. V. Kremneva, et al.
Published: (2005-04-01)

EFFECTS OF TRIMETAZIDINE ON THE TRANSMITRAL BLOOD FLOW IN PATIENTS WITH DIASTOLIC HEART FAILURE
by: Yu. N. Fedulaev, et al.
Published: (2015-09-01)

Trimetazidine effects on red blood cell membrane lipids and necrosis area size in thrombolytic therapy of myocardial infarction
by: T. Yu. Rebrova, et al.
Published: (2009-04-01)

Pharmacological treatment of stable angina pectoris: the place of trimetazidine
by: E. A. Temnikova
Published: (2022-12-01)

New potential of Trimetazidine MB for coronary heart disease treatment in the real-world clinical practice: results of the Russian multi-centre randomised study PERSPECTIVE (Part II)
by: M. G. Bubnova, et al.
Published: (2011-12-01)

ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS
by: Lei Zhang, et al.
Published: (2015-12-01)

Trimetazidine effects on intracellular Са2+ ion concentration in HL-60 human promyelocytes
by: E. I. Astashkin, et al.
Published: (2008-10-01)

Rezul'taty primeneniya preduktala (trimetazidina) u pozhilykh patsientov s refrakternoy stenokardiey, stradayushchikh sakharnym diabetom
by: A A Smirnov, et al.
Published: (2001-09-01)

Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action
by: A. Yu. Gasparyan, et al.
Published: (2008-08-01)

Biological mechanisms of natural cytoprotection - a promising trend in the development of new medicines aimed at prevention and treatment of preeclampsia
by: M. V. Pokrovsky, et al.
Published: (2018-02-01)

Trimetazidine effects on heart and kidney functional status, and quality of life in long-term complex treatment of chronic heart failure in elderly patients
by: M. E. Statsenko, et al.
Published: (2005-10-01)

To the question of the prevention of severe pre-eclampsia in pregnant women with metabolic syndrome
by: I V Savel'eva, et al.
Published: (2012-09-01)

Results of Holter monitoring in patients with angina pectoris treated by combination of trimethazidine with fabomotisol in the area of former armed conflict
by: Z. Yu. Shakhbieva, et al.
Published: (2019-06-01)

Screening in early pregnancy: is it possible to forecast the formation kardioplatsentarnoy insufficiency in preeclampsia
by: A E Kasparova, et al.
Published: (2011-12-01)

Primenenie Trimetazidina u pozhilykh patsientov s refrakternoy stenokardiey, stradayushchikh sakharnym diabetom
by: A A Smirnov, et al.
Published: (2003-06-01)

Adaptational role of mitochondrial changes in congenital central core myopathy: new proofs
by: I. S. Vinogradskaya, et al.
Published: (2016-03-01)

Spinal Anesthesia in Pregnant Females with Preeclampsia
by: Ye. M. Shifman, et al.
Published: (2007-12-01)